Communications

Advertising Communications Graphic Design Internet Marketing Media Publishing SEO
News Release Digital Asset Direct

Melissa & Doug Toys Co-founder Introduces Lifelines, Well Being Tools That Activate Senses, Promote Stress Relief

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/ytMbkUGV8kg It’s no secret that stress relief can get stressful for many people. Science tells us that 80% of stress relief starts in your body, not your brain. What if there was a way to bring stress relief to your fingertips with a science-backed collection of physical tools designed to activate the nervous system's calming response. Melissa Bernstein, the creative Founder behind Melissa & Doug Toys, is introducing her newest venture, Lifelines, a collection of Sensory Immersion™ tools that activate the body's natural stress relievers, your senses. For more than 30 years, Melissa conceived over 10,000 toys designed to unleash children's imagination, but behind-the-scenes she hid a lifelong struggle with anxiety, depression and stress. When she immersed her senses - she was able to break the cycle of rumination and experience the present moment in totality. That is the backstory and inspiration for Lifelines. Lifelines will offer a comprehensive suite of Sensory Immersion tools across all six senses. The first collection is focused on aroma, a powerful and science-backed category Melissa felt lacked innovation. The collection includes 45 products with 16 patents pending, spanning portable fidget tools, sensory writing, innovative diffusers, and essential oil blends. There are over 100 new products in development, including meditative art activities for adults and multi-sensorial sound and sight devices. Lifelines Grounding Stones are patent-pending handheld diffusers designed for touch, combining the power of scent with fidgeting. Fidgeting has been scientifically proven to reduce stress and improve focus. The six unique and touchable designs feature an irresistible swivel and fit perfectly in the palm, for stress relief anytime, anywhere. Lifelines sensory writing tools inspire focus and spark creativity. The Scented Colored Pencils elevate any writing experience. And the Pen Diffuser combines an innovative writing tool with four distinct aromas dispensed at your fingertips. Tactile Sensory Journals feature covers made for touch, with soothing embossed patterns inside to keep your ideas flowing. Lifelines immersive diffusers pair with any of their 20 essential oil blends to activate smell, touch, and sight. The Waves Ultrasonic Diffuser combines breathtaking scents, colorful lights, and cascading mist inspired by the ocean's tides. The Shower Diffuser and Bath Diffuser turn any bathroom into a spa-like getaway. The portable and lightweight Everyday Diffuser fits perfectly into small spaces like a drawer, car or bag with no batteries or cords required. And then there are Lifelines Essential Oil Blends, thoughtfully crafted aromas inspired by nature and curated by Melissa. This includes more than 20 different blends across five intoxicating scent families and four well- being goals: Energy, Calm, Focus, and Joy. Blends are made from naturally derived, sustainably sourced botanicals, free from parabens and dyes, and blended in the USA. All oils come with Lifelines' patent-pending Precision Pump™ for a mess-free application that dispenses the perfect amount of oil every time. Lifelines products are affordably priced from $5.99-$29.99 and available at popular retailers nationwide including Target. For more information, visit Lifelines.com About Lifelines Founded in 2022, Lifelines, is a collection of Sensory Immersion™ tools that activate the body's natural stress relievers, the senses. From the creative mind of toy maker and play expert, Melissa Bernstein, Lifelines established a new category of adult well-being products that are affordably priced and accessible at major retailers nationwide. For more information visit www.Lifelines.com. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 28, 2023 03:00 PM Eastern Standard Time

Video

Knightscope 9-Month Financial Report: Company Triples Net Revenue, Reduces Backlog

Benzinga

By Faith Ashmore, Benzinga Click here to learn more about the Knightscope Public Safety Infrastructure Bond. Technology is advancing quicker than ever with robotics, AI and space technology becoming not just possible but integrated into everyday life. The robotics market was valued at $31.38 billion in 2021 and is expected to reach $110.39 billion by 2030 with a CAGR of 15% from 2022-2030. Similarly, the AI market had a valuation of $454.12 billion in 2022 and is projected to reach approximately $2,575.16 billion by 2032, with a CAGR of 19% between 2023 and 2032. While things like mainstream AI adoption raised questions just 10 years ago, it is undoubtedly the way of the future. One company, in particular, took a gamble ten years ago and started combining technology in multiple multi-billion dollar markets such as robotics, AI, electric vehicles (EV), telecommunications and autonomous tech. Knightscope (NASDAQ: KSCP) is a technology company ushering in the dawn of Autonomous Security Robots (ASRs) and working hard to protect U.S. citizens from crime across the country. Its robots are designed to deter, detect and report potential security threats, providing valuable situational awareness to security and public safety professionals. Q3 Earnings Report Knightscope reported financial results for the nine months ending on September 30th, 2023. The company's net revenue for this period was approximately $9.8 million, which is almost triple the $3.3 million reported during the same time frame in 2022. This translates to an annual revenue run rate of around $13 million, which is more than double the previous year's net revenue of $5.6 million. The backlog for the company as of October 29th, 2023 was approximately $4.1 million, reflecting a decrease from the previous quarter. The backlog is subject to fluctuations as new orders come in, and the company has made significant progress in reducing its backlog. Although the backlog for autonomous security robots slightly increased, the backlog for K1B products was reduced by approximately $1.1 million. Knightscope has been working to improve its production and supply chain processes to increase production output. With these efforts and the scaling up of operations, the company has improved its gross margins. During the first nine months of 2022, Knightscope had a gross loss of $2.1 million, while during the same period in 2023, the gross loss was only $154,000. The company expects to see continued improvements in the future as it executes its plan for profitability. The company's performance has also improved on a per-share basis. The loss per common share for the period decreased from $0.40 to $0.26. As of September 30th, 2023, Knightscope had cash and cash equivalents of $4.6 million, and on December 31st, 2022, it had $4.8 million. The company also fully extinguished convertible notes secured in connection with the acquisition of CASE emergency systems by the end of the second quarter of 2023. Bond Offering Knightscope recently launched its public safety infrastructure bond offering. It is offering 10% interest, paid in cash annually, on up to a 5-year bond. For example, a $10,000 investment could yield $1,000 of interest in cash payments annually for 5 years. The company plans to conduct rolling closes of the bonds on a monthly basis and successfully completed its initial closing a few weeks ago. Investors begin earning interest on their closing date, and the bond offering will remain active for several months as per Reg A+ offering regulations. Contracts Heading Into 2024 Knightscope’s success has garnered national attention, and the company has won corporate contracts with major corporations such as PENN Entertainment (NASDAQ: PENN), PG&E (NYSE: PCG), ABM (NYSE: ABM) and Lowe's (NYSE: LOW). The company also recently announced a collaboration with the NYPD and MTA in New York City, as their robots will operate in the subway system during late-night hours. Known for their effectiveness and approachability, the K5 robots strike a balance between engagement and respect for privacy. These partnerships are among a long list of other collaborations. Knightscope also offers an educational series about the increasing role robots are playing in the economy today and the company’s mission to “make the United States the safest country in the world.” Click here to learn more about the Rise of the Robots. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT IS AVAILABLE HERE. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 28, 2023 09:55 AM Eastern Standard Time

Harnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio’s Innovative Approach

Benzinga

By Faith Ashmore, Benzinga Why Are Gamma-Delta T Cells Important In Fighting Cancer? Gamma-delta T cells belong to a unique group of immune cells that have qualities of both the innate and adaptive immune systems. They have a complex set of receptors that allow them to differentiate between healthy and cancerous cells. Their multifunctional nature enables them to directly kill cancer cells and activate other immune cells to destroy tumors. What makes gamma-delta T cells particularly promising is that they can eliminate cancer cells without prior exposure to a specific antigen. This means they can trigger a more comprehensive immune response, making them valuable candidates for both solid and hematological cancer therapies. Gamma-delta T cells are also more durable than other innate immune cells like Natural Killer (NK) cells, which have shown to be less effective in clinical trials because of lack of persistence. How IN8bio’s Innovative Platform Helps Advance This Promising Research Field IN8bio's innovative DeltEx platform forms the basis of its extensive pipeline, comprising both preclinical and clinical product candidates. The platform is specifically designed to target cancer cells effectively, with the ultimate goal of potentially eradicating them and improving patient outcomes. Central to IN8bio's approach is their advanced expertise in genetically engineering and manufacturing ex-vivo, expanded and activated gamma-delta T cells. This expertise allows them to produce these immune cells in a way that enhances their therapeutic potential. In addition, IN8bio has developed proprietary gamma-delta T-cell engineering techniques that are unique to the field. This engineering is aimed at improving the cells' resistance to chemotherapy, making them even more effective in combating cancer. Another key feature of the DeltEx platform is the use of proprietary advanced, next-generation closed-system manufacturing technology. This scalable method enables the efficient production of gamma-delta T cells – ensuring a consistent and reliable supply for potential treatments. Importantly, IN8bio's engineered DeltEx cells show broad applicability across multiple types of cancers, both solid tumors and hematological malignancies. These unique properties have resulted in scientists focusing on developing cancer therapies based on gamma-delta T cells. It is projected that by 2028, the gamma-delta T cell cancer therapy market will be at $4 billion and one company seems to be leading the charge, IN8bio (NASDAQ: INAB). IN8bio is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these cells to effectively target and eliminate cancer cells in both solid and hematological tumors. IN8bio's pipeline consists of a range of preclinical and clinical investigational therapies that aim to address various types of cancer with large unmet needs. Many of its lead product candidates are being developed for the treatment of patients with advanced solid tumors. The solid tumor market was valued at $209.61 billion in 2021, and it's expected to reach $901.27 billion by 2029. The drug candidate, INB-200, may be useful in treating solid tumors, including glioblastoma (GBM). GBM is a highly aggressive type of brain cancer with no cure, leading to a grim prognosis and an average overall survival time of only 14 to 16 months. INB-200 is a genetically modified autologous product candidate. This novel platform called drug-resistant immunotherapy, or DRI, utilizes genetic engineering to generate chemotherapy-resistant gamma delta T cells that can be administered concurrently with standard-of-care treatment in solid tumors. This is a powerful, synergistic treatment approach enabling gamma-delta T cells to persist in the presence of chemotherapy and maintain their natural ability to recognize, engage and kill cancer cells. It is designed to activate and expand Gamma-delta T cells in order to enhance the body's immune response against cancer. Leukemia, with a specific focus on Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), is another area of interest for IN8bio. The AML market is projected to to grow from $3.5 billion in 2022 to $6.1 billion in 2028 – representing a CAGR of 10%, while the MDS market which was worth $ 3.3 billion in 2022 is expected to exhibit a CAGR of 9.3% over 2023-2030. IN8bio's INB-100 is an allogeneic-derived, gamma-delta T cell product candidate aimed at addressing the unmet need in these areas. While there are some companies, such as Adicet (NASDAQ: ACET) and Century Therapeutics (NASDAQ: IPSC), studying gamma-delta T cells, IN8bio's DeltEx platform sets them apart from competitors in the field of cancer therapy. Its expertise, proprietary techniques, and scalable manufacturing process potentially position it as a leader in harnessing the potential of gamma-delta T cells for the development of innovative and effective cancer treatments. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 28, 2023 09:55 AM Eastern Standard Time

Lytus Digital Spearheads Lytus' Expansion Into The Next-Generation Technology Space

Benzinga

By Meg Flippin, Benzinga Macro headwinds may be impacting the economy along with geopolitical tensions, but that isn’t stopping businesses from looking to invest in their technology and IT solutions focused on business transformation and improved customer offerings. For 2023, worldwide IT spending is forecast to reach $4.6 trillion. Lytus Technologies recognizes the growing global demand for technology engineering services and aims to fulfill it through Lytus Digital. Driving a lot of that growth is spending on software. Forecasts estimate software sales will increase 12.3% in 2023 and 13.1% in 2024. Companies are looking to increase automation and productivity and are spending their investment dollars on software to achieve that. Need For Digital Transformation In recent years, digital business strategy has had a growing influence on overall business strategy which has resulted in companies leveraging technological solutions to transform their operations and improve their value proposition. A recent Gartner survey highlighted the demand for these services with 89% of board directors recognising the need for technological solutions but only 35% having achieved their digital transformation goals. Lytus Technologies’ new venture aims to serve the needs of the global SME sector which accounts for 90% of businesses and more than 50% of employment worldwide. Lytus Digital reports that it offers a suite of high-quality technology solutions that leverage several leading-edge technologies like cloud computing, wireless sensor networks and low-code rapid application development frameworks to address a wide range of enterprise pain points, and it makes these solutions accessible to a larger customer demographic across the globe. Winning Isn’t Easy Lytus Digital reports it is working on a range of exciting projects in its pipeline that address the major challenges faced by global enterprises in terms of building their digital presence, facilitating better business practices and improving customer interactions. The company is developing an ecosystem of customizable platforms focused on streamlining business process management, finance and compliance systems. This ecosystem will be integrated with The Next Generation E-commerce Platform featuring virtual and mixed-reality experiences. The company aims to remain at the forefront of innovation by leveraging deep tech like AI-assisted automation, computer vision machine learning and natural language processing. “Lytus Digital operates in a market where the barrier to entry is providing value to customers at aggressive thresholds,” said Lytus Digital’s Co-Head Jugal Gala when announcing the new offering. “Our in-house engineering capabilities will help us break into the market profitably. With this pursuit, we aim to establish strong partnerships in the industry to boost multinational growth, and to build accessible leading-edge technology-enabled products and solutions across various verticals.” Emerging Tech Brand By entering the technology engineering sector, Lytus is not just tapping an underserved need, but is positioning itself as an emerging competitive tech brand serving global markets The company’s business model is potentially disruptive but easily repeatable and scalable across geographies. Its recent launch of Lytus Studios is another example of how the company is leveraging technology to serve growing markets. Lytus Studios is a content creation and technology services business bringing virtual reality, augmented reality, mixed reality and extended reality to the film, video, commercial, corporate and digital markets. “This venture brings a strong tech native presence into our fold of companies and further strengthens Lytus’s ambitions to emerge as a leading technology brand in the global markets,” said Lytus Technologies CEO Dharmesh Pandya. “We are confident that the Lytus Digital team, with their strong engineering capabilities, will have a positive impact on our offerings and revenues.” Lytus Technologies is a platform services company enriching the experience for users whether it’s streaming content, telemedicine or fintech services. The company reports that its ability to provide a cutting-edge platform regardless of the digital offering is what makes it unique. The company operates telecasting, telemedicine and OTT platforms, leveraging its 5,000-kilometer network of installed fiber and broadband infrastructure to serve more than four million users in India and the USA. It's one of the few Indian companies listed on the NASDAQ. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 28, 2023 09:55 AM Eastern Standard Time

This Junior Miner Recently Secured Massive Investment From A Big 3 Automaker – A Closer Look At Argentina Lithium & Energy Corp. (TSX-V: LIT) (OTCM: PNXLF)

Benzinga

By Austin DeNoce, Benzinga Argentina Lithium & Energy Corp. (TSX-V: LIT, OTCM: PNXLF) recently closed a $90 million (in Argentina peso equivalent) investment deal, marking a pivotal moment in its growth and potential impact on the lithium industry. In light of this new round of funding, below is a comprehensive look at the company’s current position in the lithium sector by exploring the company’s profile, management and the strategic significance of the latest financial injection. Company Overview Argentina Lithium & Energy Corp. is a specialized mineral exploration entity with a concentrated focus on lithium. The company operates under the umbrella of the Grosso Group and focuses on acquiring and advancing lithium projects to meet the growing global demand from the battery sector. The company boasts a significant portfolio of more than 67,000 hectares of claims in the Lithium Triangle, known for containing over 75% of the world’s lithium resources. With aggressive exploration programs and a strategic location in mining-friendly provinces, the company has its sights set on growth. Its Rincon West project, for example, is notable for its significant lithium concentrations and proximity to other major development projects. Management Team The leadership of Argentina Lithium comprises individuals with extensive experience in mineral exploration and corporate governance. Nikolaos Cacos, at the helm as President and CEO, brings over three decades of expertise in the junior mining sector, and Vice President of Exploration Miles Rideout also has over 30 years of experience in exploration and social and community relations. The Company’s board of directors brings a breadth of technical and financial acumen. The $90 Million Investment Argentina Lithium’s growth trajectory has been significantly bolstered by a $90 million investment in Argentina peso equivalent by Stellantis N.V. (NYSE: STLA), one of the Big Three American automakers looking to make its mark in the electric vehicle arena. The company secured a 19.9% ownership in Argentina Lithium's subsidiary via its own Argentine subsidiary. This partnership includes a lithium offtake agreement and future investor rights, suggesting a long-term commitment to the company’s success and setting the stage for expanded development and corporate purposes. Lithium’s Global Significance Lithium’s importance spans industrial, technological and medical applications. It is pivotal in the production of heat-resistant glass and ceramics, plays a critical role in aircraft construction and serves as a mood stabilizer in medical treatments. However, perhaps most important of all, lithium is indispensable for the electric vehicle (EV) industry. Lithium-ion batteries, utilized for their efficiency and high energy storage capacity, are the linchpin in EV performance, dictating battery range. Approximately eight kilos of lithium carbonate are used in the average EV battery system, underlining the extensive demand for lithium as EV adoption accelerates. Continuous improvements in lithium battery technology are enhancing the performance of EVs, reinforcing lithium’s central role in the transition to low-carbon transportation. Exploring The Future The strategic movements of Argentina Lithium & Energy Corp., supported by a seasoned management team and a significant investment from an industry leader like Stellantis, potentially position the company as one to watch in the lithium exploration arena. The stage seems set for mass electric vehicle adoption and the expected accompanying surge in demand for lithium. Now, it’s all about execution and capitalizing on this growth potential. Benzinga has been compensated by Argentina Lithium & Energy for publicizing this content. This content is for informational purposes only and not intended to be investing advice. Please read our Partner Disclosure for more information. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 28, 2023 09:55 AM Eastern Standard Time

Steakholder’s (NASDAQ: STKH) New Beef Ink Is Helping Make Commercial-Scale Steak Printing A Reality

Benzinga

By Rachael Green, Benzinga Last month, Steakholder Foods (NASDAQ: STKH) launched Beef Steak Ink, the latest in its line of plant-based meat inks made for the company’s proprietary 3D bioprinter. The Israel-based 3D bioprinting cultivated meat company is a leader in the emerging lab-grown meat market thanks to its innovative technology that aims to give manufacturers a scalable, easy-to-adopt solution for developing hybrid (cultivated meat mixed with plant-based) products with realistic flavor and texture. Steakholder Foods Reports Its Ink And Printer Tech Make Cultivated Meat More Realistic And Easier To Produce At Scale At the heart of the B2B-focused company’s offering is the 3D printing technology designed to realistically mimic the texture of different cuts of meat. While researchers have been experimenting with cultivating meat cells in a lab for a while, one of the key challenges they’ve struggled to overcome is achieving the right texture. The flakiness of a fish fillet or the tender yet fibrous mouthfeel of a steak comes largely from the way muscle and fat cells grow inside a living, moving animal. As such, mimicking that texture with lab-grown cells is challenging, and many of the cultivated meat products on the market today are modeled on easier-to-mimic textures like meatloaf, meatballs and patties. With Steakholder Foods’ 3D printers and ink, however, achieving the texture of more complicated cuts like fish fillets or steaks is becoming possible. The ink is made with plant-based ingredients formulated to mimic the taste, texture and appearance of the meat they will become. After adding the desired proportion of cultivated cells, the printer can produce a structured hybrid product in a matter of minutes that’s ready to cook. Steakholder Foods’ 3D Bioprinting Process Finally Gives Businesses A Way To Potentially Efficiently Produce Hybrid Products At Commercial Scale The 3D printing process is completely controlled digitally and can go from digital design to ready-to-cook product in a matter of minutes. By combining that speed with the fully automated function of Fusion Pro 3D bioprinter, Steakholder Foods seems to have broken through one of the key barriers that had been holding manufacturers back from developing cultured meat products: scalability. With this industrial-scale technology, manufacturers finally have a way to produce tons of Hybrid meat products per month. Once the user designs the product they want in the software, the 3D printer can get to work perfectly recreating that design over and over again. Investors will have a chance to see that scalability in action as the company signed its first multimillion-dollar agreement in July to establish a large-scale production facility. The pilot facility will be built in partnership with a Gulf Cooperation Council-based government body in the Persian Gulf. “After intensive years of development, Steakholder Foods is excited to sign this first agreement with a strategic partner, generating our first income stream that represents one of the first substantial income agreements for a company in the cultivated meat industry, a huge step forward,” said Steakholder Foods CEO Arik Kaufman in a statement on the news. The launch of beef ink is part of Steakholder Foods’ broader strategy to develop a diverse portfolio of hybrid meat products that businesses can use to create realistic cuts of meat or design innovative products that would have been impossible with traditional meat. After the initial sale of the 3D printer to businesses looking to develop their own custom-cultivated meat products, this growing portfolio of inks is expected to serve as a source of recurring revenue for Steakholder Foods. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 28, 2023 09:55 AM Eastern Standard Time

Benzinga To Host Exclusive Free ETFs Unlocked Webinar on November 30; Several Notable Voices to Discuss How ETFs Offer Investors Diversification And Exposure to Broad Range of Assets

Benzinga

To register for free and secure your spot at the ETFs Unlocked Webinar, click here. Benzinga, a leading financial media and events company, is thrilled to announce the upcoming ETFs Unlocked Webinar, a thought-provoking virtual panel discussion on navigating investment strategies in the evolving financial landscape as we approach 2024. The event is scheduled for November 30, and free registration is open to all. As the financial landscape undergoes changes, investors are increasingly drawn to Exchange-Traded Funds (ETFs) for various reasons. One key factor driving this trend is the appeal of a diversified approach to investing, particularly in the face of economic uncertainty. ETFs offer investors exposure to a broad range of assets, such as stocks, bonds, or commodities, providing a way to spread risk across various sectors and industries. This diversification can act as a risk management tool, helping investors navigate volatile market conditions more effectively. For sophisticated traders, leveraged ETFs have gained popularity due to their ability to amplify both upward and inverse moves in single stocks. This feature allows traders to potentially maximize returns in a relatively short period. The growing interest in ETFs reflects a broader shift in investment strategies, with investors increasingly valuing the versatility, diversification, and potential for short-term gains that these funds offer in today’s financial landscape. The ETFs Unlocked Webinar will delve into crucial topics such as: Outlook for Investments in a Changing Economic Environment: Examining how evolving economic conditions may affect investment strategies. Identifying sectors poised for strong performance in the shifting financial landscape. Sectors to Watch for Continued Strength: Exploring sectors that offer potential opportunities for investors amid changing market dynamics. Highlighting strategies for navigating a dynamic economic environment. Focus on Sectors During Economic Transitions: Discussing sectors that should be in focus during economic transitions. Impact of Market Conditions on Various Investment Categories: Analyzing how changing market conditions influence the performance of different investment categories. Performance of Investment Income Streams: Addressing the critical question of how investment income streams are expected to perform in the coming year. This engaging panel discussion will feature industry experts including Dave Gilreath CFP®, Managing Director and Chief Investment Officer at Innovative Portfolios; Yuri Khodjamirian, CIO at Tema ETFs; Eva Ados, COO & Chief Investment Strategist, ERShares; Joel Shulman, CEO at ERShares; John Ciampaglia, CEO at Sprott Asset Management; Daniel Santiago, Vice President, VantagePoint Software; and Sylvia Jablonski, CEO, CIO at DeFiance ETFs. Attendees will have the opportunity to gain valuable insights from these esteemed speakers, making the ETFs Unlocked Webinar a must-attend event for investors and financial professionals. To register for free and secure your spot at the ETFs Unlocked Webinar, please visit the Benzinga Virtual Events Registration Page. Event Details: Date: November 30, 2023 Time: 11:00 am, EST Location: Virtual Event https://youtube.com/live/yFfR-NSqnng?feature=share Partners of the Event: Dave Gilreath CFP®, Managing Director and Chief Investment Officer, Innovative Portfolios Yuri Khodjamirian, CIO, Tema ETFs Eva Ados, COO & Chief Investment Strategist, ERShares Joel Shulman, CEO, ERShares John Ciampaglia, CEO, Sprott Asset Management Sylvia Jablonski, CEO, CIO, DeFiance ETFs Daniel Santiago, Vice President, VantagePoint Software Don't miss this unique opportunity to stay ahead in the financial landscape. Register today for the ETFs Unlocked Webinar and unlock the insights you need for a successful investment strategy. For media inquiries, please contact Matt Steinmetz, Vice President of Virtual Events at Benzinga. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 28, 2023 09:19 AM Eastern Standard Time

Introducing Doceree Insights: Revolutionizing Healthcare Marketing Analytics with the Power of AI

Doceree Inc

Today, Doceree, the leading global platform building unprecedented solutions for healthcare professional (HCP) messaging, proudly unveils its new groundbreaking offering – Insights. Inspired by tools like ChatGPT, this innovative solution transforms the way healthcare marketers access and interpret data. As the latest addition to the suite of AI-powered tools on the platform, Insights empowers healthcare marketers with a game-changing approach to analytics, making it easier than ever to unravel crucial business insights from your marketing campaigns. Healthcare marketers often know the business questions they need answered, but don’t always know what data and analytics will help them find those answers. At the heart of Insights is the ability for marketers to pose those questions directly to the platform, and in return, Insights provides data-driven answers in the form of interactive, exportable data visualizations. In an industry marked by evolving trends and ever-increasing demands, healthcare marketers face the challenge of understanding their campaign performance and making data-driven decisions. To address this need, Doceree has developed Insights, a ChatGPT-style tool designed to simplify the analytics process with on-demand access to vital information quickly and effortlessly. With Insights, marketers can explore all their campaign data – including physician and provider level data (PLD). By leveraging Doceree’s proprietary HCP identity-resolution technology Espyian TM, Insights can answer detailed questions about campaign performance at the individual level. Data and analytics that were previously fragmented and complex, are now easily accessible on-demand with this innovative tool. Using artificial intelligence, Insights harnesses the power of natural language processing (NLP) to interpret and understand the marketer’s question and get them the answer they seek. Insights eliminates the need to sift through static charts and predefined dashboards that often hinder quick and efficient data exploration. This interactive, AI-powered tool also allows users to export and incorporate the right data and visualizations into their own branded presentations, making it even easier for marketers to tell their story with data. “ Doceree is committed to finding the bottlenecks in pharma messaging and bridging them with its AI-powered, category-focused platform and end-to-end solutions that allow pharma marketers to activate top-performing campaigns, while also effectively tracking their KPIs. With our new offering- Insights, we are set to revolutionize healthcare marketing analytics, making data-driven decisions for pharma marketers, as easy as asking a question,” said Harshit Jain MD, Founder & Global CEO at Doceree. In the competitive landscape of healthcare marketing analytics, Insights stands out as a powerful tool that simplifies the process of understanding campaign performance. By allowing customers to pose questions directly to the platform, they can quickly identify and access the precise data they require, without the need for advanced analytics skills. Key Benefits of Doceree Insights: Intuitive & AI-Powered | Helps find actionable insights and answers to questions quickly, easily, without the need for advanced analytical skills Exportable | Enables pharma marketers to tell their story their way, by allowing incorporation of the right data and visualizations into branded presentations and other materials with the ‘Export’ function On-Demand | Eliminates the frustration and inflexibility of static charts and predefined dashboards; marketers can simply ask questions and Insights will return the precise data in the form of interactive visualizations. Doceree Insights is available for healthcare marketers across the globe. For more information about Insights and how it can transform healthcare marketing analytics, please visit https://doceree.com/us/doceree-insights/ or contact partner@doceree.com. About Doceree Doceree is a global platform building unique solutions for healthcare professional (HCP) programmatic messaging with proprietary data tools. It facilitates messaging between life sciences brands and HCPs through an extensive global network of digital endemic and point-of-care platforms to programmatically deliver personalized communications to HCPs at scale. To learn more, visit doceree.com. Contact Details Priyanka Bhasin +91 78387 03702 priyanka.bhasin@doceree.com Tanya Singh +91 70420 89805 tanya.singh@doceree.com Company Website https://doceree.com/us/

November 28, 2023 08:30 AM Eastern Standard Time

Image

Doceree introduces AI-powered Insights to revolutionize Analytics in Pharma Marketing

Doceree Inc

Doceree, the leading global platform building unprecedented solutions for healthcare professional (HCP) messaging, today unveiled its groundbreaking new offering – Insights. Inspired by tools like ChatGPT, this innovative solution is set to transform the way pharma marketers access and interpret data. As the latest addition to the suite of AI-powered tools on the platform, Insights will empower healthcare marketers with a game-changing approach to analytics, making it easier than ever to unravel crucial business insights from marketing campaigns. In an industry marked by evolving trends and ever-increasing demands, pharma marketers face the challenge of understanding their campaign performance and making data-driven decisions. They often know the business questions they need answered, but don’t always know what data and analytics will help them find those answers. To address this need, Doceree developed Insights to simplify the analytics process with on-demand access to vital information quickly and effortlessly. With Insights, pharma marketers can explore all their campaign data by simply posing campaign related questions directly to the platform and receive data-driven answers in the form of interactive, exportable data visualizations. Leveraging Doceree’s proprietary HCP identity-resolution technology Espyian TM, Insights is designed to make data and analytics easily accessible and on-demand, that was previously fragmented and complex. Using artificial intelligence, Insights harnesses the power of natural language processing (NLP) to interpret and understand pharma marketers’ questions and get them the answers they seek. Insights eliminates the need to sift through static charts and predefined dashboards that often hinder quick and efficient data exploration. The interactive, AI-powered tool also allows users to export and incorporate the right data and visualizations into their own branded presentations, making it easier for marketers to tell their story with data. “ Doceree is committed to finding the bottlenecks in pharma messaging and bridging them with its AI-powered, category-focused platform and end-to-end solutions that allow pharma marketers to activate top-performing campaigns, while also effectively tracking their KPIs. With our new offering- Insights, we are set to revolutionize healthcare marketing analytics, making data-driven decisions for pharma marketers, as easy as asking a question,” said Harshit Jain MD, Founder & Global CEO at Doceree. In the competitive landscape of healthcare marketing analytics, Insights stands out as a powerful tool that simplifies the process of understanding campaign performance. By allowing customers to pose questions directly to the platform, they can quickly identify and access the precise data they require, without the need for advanced analytics skills. Key Benefits of Doceree Insights: Intuitive & AI-Powered | Helps find actionable insights and answers to questions quickly, easily, without the need for advanced analytical skills Exportable | Enables pharma marketers to tell their story their way, by allowing incorporation of the right data and visualizations into branded presentations and other materials with the ‘Export’ function On-Demand | Eliminates the frustration and inflexibility of static charts and predefined dashboards; marketers can simply ask questions and Insights will return the precise data in the form of interactive visualizations. Doceree Insights is available for healthcare marketers across the globe. For more information about Insights and how it can transform healthcare marketing analytics, please visit https://doceree.com/uk/doceree-insights/ or contact partner@doceree.com. About Doceree Doceree, the world's first global network of physician-only platforms, offers a cutting-edge solution to programmatically reach HCPs where they consume information in their professional mindset, including medical journals, education platforms, and physician networks. Their proprietary physician identity resolution technology, ESPYIANTM, allows brands to showcase the right information to the right physician at the most opportune moments based on their specialty, location, and professional interests. To learn more, visit https://doceree.com/uk/ Contact Details Priyanka Bhasin +91 78387 03702 priyanka.bhasin@doceree.com Tanya Singh +91 70420 89805 tanya.singh@doceree.com Company Website https://doceree.com/uk/

November 28, 2023 08:00 AM Eastern Standard Time

Image

1 ... 50 51 52 53 54 ... 345